A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Lymphoma, Large B-Cell, Diffuse (DLBCL)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Jul 14, 2022
- Main results expected
- Apr 26, 2029
- Fully finished
- Apr 26, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1
Measured over: Cycle 1 (up to 21 days)
Number of Participants Who Experienced At Least One AE
Measured over: Up to approximately 8 months
Number of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to approximately 5.5 months
Complete Response Rate (CRR) per Lugano Response Criteria
Measured over: Up to approximately 60 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05406401 · record last updated 2024-10-15 · checked 2026-11-09 15:47 UTC